Sandoz will be the leading biosimilar drug company in 2012, with revenue of $308 million predicts n

A new report by Visiongain predicts that Sandoz will retain its position as the global leader in the biosimilar drugs market in 2012. PRLog (Press Release) – Oct 18, 2012 – In that year, its three follow-on biologics will achieve $308m in revenue.